AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11077390 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold testing of the root
Number of subjects: 16
Study 8797468 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine hydrochloride (ALCAR) 3 g/day
Number of subjects: 431
Study 8797468 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 g tid)
Number of subjects: 431
Study 8797468 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine hydrochloride (ALCAR)
Number of subjects: 431
Study 8797468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 431
Study 1521671 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day zolpidem
Number of subjects: 119
Study 1521671 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day zolpidem
Number of subjects: 119
Study 1521671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 6220336 — intervention group
Group type: EXPERIMENTAL
Intervention: Duxil
Number of subjects: 0
Study 6220336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30703126 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash transfer intervention (conditional or unconditional on school enrollment)
Number of subjects: 1708
Study 30703126 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cash transfer)
Number of subjects: 1708
Study 29913528 — intervention group
Group type: EXPERIMENTAL
Intervention: Camphor-Crataegus Combination (CCC) - 20 drops of a fixed combination of natural D-camphor and an ethanolic extract from fresh Crataegus berries
Number of subjects: 0
Study 29913528 — intervention group
Group type: COMPARATOR
Intervention: Placebo (ethanolic placebo)
Number of subjects: 0
Study 27074340 — intervention group
Group type: EXPERIMENTAL
Intervention: Crack/cocaine exposure in utero (EN)
Number of subjects: 156
Study 27074340 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal history of crack/cocaine use
Number of subjects: 156
Study 23916115 — intervention group
Group type: EXPERIMENTAL
Intervention: F‐SCLs
Number of subjects: 16
Study 23916115 — intervention group
Group type: COMPARATOR
Intervention: S‐SCLs
Number of subjects: 16
Study 22385586 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (written and oral program on hypertension and cardiovascular risk)
Number of subjects: 120
Study 22385586 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study 19290011 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle interventions
Number of subjects: 1916
Study 17198742 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin and multimineral supplementation (one tablet daily)
Number of subjects: 910
Study 17198742 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo tablet daily)
Number of subjects: 910
Study 15030624 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessment of intentions
Number of subjects: 0
Study 15030624 — intervention group
Group type: COMPARATOR
Intervention: Evaluation of others' intentions
Number of subjects: 0
Study 11588818 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd‐YAG laser irradiation with acidulated phosphate fluoride solution (APF)
Number of subjects: 20
Study 11588818 — intervention group
Group type: COMPARATOR
Intervention: Control group (no laser treatment)
Number of subjects: 20
Study 9521392 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-gloving method
Number of subjects: 2058
Study 9521392 — intervention group
Group type: COMPARATOR
Intervention: Single-gloving method
Number of subjects: 2058
Study 9521392 — intervention group
Group type: EXPERIMENTAL
Intervention: Double outer-gloves
Number of subjects: 2058
Study 9521392 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched outer and inner perforation
Number of subjects: 2058
Study 8019170 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor exercise only (group A)
Number of subjects: 46
Study 8019170 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor exercise plus vaginal cones (group B)
Number of subjects: 46
Study 2609138 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid
Number of subjects: 14
Study 1092419 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 70
Number of subjects: 831
Study 1092419 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 831
Study 31959492 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 50 mg BID
Number of subjects: 17
Study 31959492 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 100 mg BID
Number of subjects: 17
Study 31959492 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 200 mg BID
Number of subjects: 17
Study 31959492 — intervention group
Group type: EXPERIMENTAL
Intervention: IV paclitaxel 135 mg/m2/3 h + IV bevacizumab 15 mg/kg + IP cisplatin 75 mg/m2 + IP paclitaxel 60 mg/m2
Number of subjects: 17
Study 31959492 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance olaparib 300 mg BID and bevacizumab 15 mg/kg Day 1
Number of subjects: 17
Study 31959492 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 17
Study 29659918 — intervention group
Group type: EXPERIMENTAL
Intervention: Total dairy
Number of subjects: 91
Study 29659918 — intervention group
Group type: EXPERIMENTAL
Intervention: Unflavored milk
Number of subjects: 91
Study 29659918 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced fat dairy
Number of subjects: 91
Study 29659918 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat/fat-free dairy
Number of subjects: 91
Study 29659918 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverage intake
Number of subjects: 91
Study 28460182 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate and citrulline supplementation (1200 mg nitrate and 6 g citrulline)
Number of subjects: 14
Study 28460182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 25868877 — intervention group
Group type: EXPERIMENTAL
Intervention: TMP grade 2-3
Number of subjects: 89
Study 23991206 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL cholesterol
Number of subjects: 12
Study 20661750 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sigmoid resection (LSR)
Number of subjects: 0
Study 20661750 — intervention group
Group type: COMPARATOR
Intervention: Open sigmoid resection (OSR)
Number of subjects: 0
Study 19248193 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (20 mg o.d.)
Number of subjects: 54
Study 19248193 — intervention group
Group type: COMPARATOR
Intervention: Valsartan (80 mg o.d.)
Number of subjects: 54
Study 19248193 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Telmisartan and Valsartan
Number of subjects: 54
Study 19248193 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 54
Study 19248193 — intervention group
Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 54
Study 17393189 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cryotherapy
Number of subjects: 80
Study 17393189 — intervention group
Group type: COMPARATOR
Intervention: Standard oral care (Control)
Number of subjects: 80
Study 17393189 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cryotherapy (in autologous setting)
Number of subjects: 80
Study 14977818 — intervention group
Group type: EXPERIMENTAL
Intervention: Flt3 ligand (FL)
Number of subjects: 31
Study 14977818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 11125386 — intervention group
Group type: EXPERIMENTAL
Intervention: Periurethral autologous fat injection
Number of subjects: 68
Study 11125386 — intervention group
Group type: COMPARATOR
Intervention: Saline injection (placebo)
Number of subjects: 68
Study 11125386 — intervention group
Group type: EXPERIMENTAL
Intervention: Complications from fat injection
Number of subjects: 68
Study 9543148 — intervention group
Group type: EXPERIMENTAL
Intervention: c-kit mRNA expression detected by RT-PCR in oocytes and granulosa cells
Number of subjects: 0
Study 9543148 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble c-kit protein presence measured by Western blot analysis
Number of subjects: 0
Study 9543148 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentration of soluble c-kit in follicular fluid measured by enzyme-linked immunosorbent assay
Number of subjects: 0
Study 8047812 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg aspirin daily
Number of subjects: 45
Study 8047812 — intervention group
Group type: COMPARATOR
Intervention: No medication (control group)
Number of subjects: 45
Study 3195995 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (250 mg orally, twice daily)
Number of subjects: 45
Study 3195995 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (160 mg of trimethoprim and 800 mg of sulfamethoxazole orally, twice daily)
Number of subjects: 45
Study 3195995 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 45
Study 3195995 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 45
Study 29741660 — intervention group
Group type: EXPERIMENTAL
Intervention: IV lidocaine (75 mg if <50 kg, 100 mg if 50-100 kg, 150 mg if >100 kg) over 10 minutes, followed by a 50-minute IV lidocaine infusion of the same dose
Number of subjects: 32
Study 29741660 — intervention group
Group type: COMPARATOR
Intervention: Provider-chosen dose of morphine
Number of subjects: 32
Study 29741660 — intervention group
Group type: EXPERIMENTAL
Intervention: IV lidocaine
Number of subjects: 32
Study 29741660 — intervention group
Group type: COMPARATOR
Intervention: IV morphine
Number of subjects: 32
Study 28217891 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Behavioral Intervention (CBI)
Number of subjects: 44
Study 28217891 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care Exercise (SCE)
Number of subjects: 44
Study 25607909 — intervention group
Group type: EXPERIMENTAL
Intervention: Efinaconazole topical solution, 10%
Number of subjects: 1655
Study 25607909 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 1655
Study 24649785 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline 250 mg three times per day
Number of subjects: 60
Study 24649785 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen 500 mg three times per day
Number of subjects: 60
Study 21777163 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 404
Study 18161012 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (60 mg/day)
Number of subjects: 8
Study 18161012 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofexidine (2.4 mg/day)
Number of subjects: 8
Study 18161012 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (60 mg/day) combined with Lofexidine (2.4 mg/day)
Number of subjects: 8
Study 18161012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 16649886 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking speed measurements
Number of subjects: 73
Study 16649886 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Ambulation Categories (FAC) scores
Number of subjects: 73
Study 12648028 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg immediate‐release tablet of ximelagatran with breakfast
Number of subjects: 18
Study 12648028 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg immediate‐release tablet of ximelagatran while fasting
Number of subjects: 18
Study 12648028 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg subcutaneous injection of ximelagatran
Number of subjects: 18
Study 12648028 — intervention group
Group type: EXPERIMENTAL
Intervention: 2mg intravenous infusion of melagatran
Number of subjects: 18
Study 12648028 — intervention group
Group type: EXPERIMENTAL
Intervention: APTT measurement
Number of subjects: 18
Study 12088943 — intervention group
Group type: EXPERIMENTAL
Intervention: rapacuronium
Number of subjects: 10
Study 12088943 — intervention group
Group type: COMPARATOR
Intervention: mivacurium
Number of subjects: 10
Study 9695300 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol (0.15 mg/kg in 2 mL saline)
Number of subjects: 156
Study 9695300 — intervention group
Group type: COMPARATOR
Intervention: Saline nebulization (control group)
Number of subjects: 156
Study 9695300 — intervention group
Group type: COMPARATOR
Intervention: Mist in a tent (control group)
Number of subjects: 156
Study 7867139 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily regimen of amphotericin B (escalating dose starting at 0.05 mg/kg to 1 mg/kg, total dose of 20 mg/kg)
Number of subjects: 80
Study 7867139 — intervention group
Group type: COMPARATOR
Intervention: Alternate-day regimen of amphotericin B (escalating dose starting at 0.05 mg/kg to 1 mg/kg, then given on alternate days)
Number of subjects: 80
Study 2502344 — intervention group
Group type: EXPERIMENTAL
Intervention: Early weight-bearing
Number of subjects: 99
Study 2502344 — intervention group
Group type: COMPARATOR
Intervention: Late weight-bearing
Number of subjects: 99
Study 2502344 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal fixation with cerclage wires, staples, and pins
Number of subjects: 99
Study 335772 — intervention group
Group type: EXPERIMENTAL
Intervention: SnF2 (0.2%)
Number of subjects: 12
Study 335772 — intervention group
Group type: EXPERIMENTAL
Intervention: SnF2 (0.3%)
Number of subjects: 12
Study 335772 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine (0.1%)
Number of subjects: 12
Study 335772 — intervention group
Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 12
Study 28279137 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized spiritual program
Number of subjects: 5339
Study 25992622 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric hyperoxia at FiO2 100% over an endotracheal tube for 3 hours
Number of subjects: 44
Study 25992622 — intervention group
Group type: COMPARATOR
Intervention: Room air
Number of subjects: 44
Study 25992622 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric hyperoxia
Number of subjects: 44
Study 23453761 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump surgery
Number of subjects: 2203
Study 23453761 — intervention group
Group type: COMPARATOR
Intervention: On-pump surgery
Number of subjects: 2203
Study 23453761 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Off-pump and On-pump)
Number of subjects: 2203
Study 21406646 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose clopidogrel (600-mg initial dose, 150 mg daily thereafter)
Number of subjects: 2214
Study 21406646 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose clopidogrel (no additional loading dose, 75 mg daily)
Number of subjects: 2214
Study 21406646 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose clopidogrel
Number of subjects: 2214
Study 21406646 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose clopidogrel
Number of subjects: 2214
Study 19090775 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula-feed (FF) with zidovudine prophylaxis
Number of subjects: 1116
Study 19090775 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feed (BF) with zidovudine prophylaxis
Number of subjects: 1116
Study 19090775 — intervention group
Group type: COMPARATOR
Intervention: Maternal receipt of nevirapine
Number of subjects: 1116
Study 19090775 — intervention group
Group type: COMPARATOR
Intervention: Maternal HIV-1 RNA levels in plasma
Number of subjects: 1116
Study 19090775 — intervention group
Group type: COMPARATOR
Intervention: Maternal HIV-1 RNA levels in breast milk
Number of subjects: 1116
Study 17014529 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonded amalgam restoration
Number of subjects: 120
Study 17014529 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonded composite resin restoration
Number of subjects: 120
Study 17014529 — intervention group
Group type: COMPARATOR
Intervention: Conventional amalgam restoration
Number of subjects: 120
Study 17014529 — intervention group
Group type: COMPARATOR
Intervention: No restoration (MOD cavities)
Number of subjects: 120
Study 17014529 — intervention group
Group type: COMPARATOR
Intervention: Endodontic access cavities prepared
Number of subjects: 120
Study 17014529 — intervention group
Group type: COMPARATOR
Intervention: Intact teeth
Number of subjects: 120
Study 12723102 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Actibrush (battery-powered toothbrush)
Number of subjects: 80
Study 12723102 — intervention group
Group type: COMPARATOR
Intervention: Crest SpinBrush (battery-powered toothbrush)
Number of subjects: 80
Study 11202860 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical retreatment
Number of subjects: 92
Study 11202860 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical retreatment
Number of subjects: 92
Study 9488197 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine-lovastatin combination therapy
Number of subjects: 0
Study 9488197 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine alone
Number of subjects: 0
Study 8363987 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiotapes of initial cancer consultation
Number of subjects: 194
Study 8363987 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised letters
Number of subjects: 194
Study 8363987 — intervention group
Group type: COMPARATOR
Intervention: Audiotapes
Number of subjects: 194
Study 30721948 — intervention group
Group type: EXPERIMENTAL
Intervention: No red meat group (N = 48)
Number of subjects: 132
Study 30721948 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber group (N = 44)
Number of subjects: 132
Study 30721948 — intervention group
Group type: COMPARATOR
Intervention: Control group (N = 40)
Number of subjects: 132
Study 28697676 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy (LST)
Number of subjects: 30
Study 28697676 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral appliance therapy (OA)
Number of subjects: 30
Study 28697676 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling (CSL)
Number of subjects: 30
Study 27126223 — intervention group
Group type: EXPERIMENTAL
Intervention: Axial implants (2 anterior/2 posterior)
Number of subjects: 41
Study 27126223 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilted implants (2 anterior axial/2 distal tilted)
Number of subjects: 41
Study 24686029 — intervention group
Group type: EXPERIMENTAL
Intervention: USG‐PVB with 30 mL of 0.5% ropivacaine (3 injections of 10 mL each at right T5 and bilateral T8)
Number of subjects: 52
Study 24686029 — intervention group
Group type: EXPERIMENTAL
Intervention: USG‐PVB with 30 mL of 0.5% ropivacaine
Number of subjects: 52
Study 24686029 — intervention group
Group type: COMPARATOR
Intervention: Saline injection of 10 mL at every site (control group)
Number of subjects: 52
Study 22612662 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal misoprostol (600 µg)
Number of subjects: 264
Study 22612662 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin infusion (20 IU in 500 mL)
Number of subjects: 264
Study 20382179 — intervention group
Group type: EXPERIMENTAL
Intervention: Keep Active Minnesota (KAM) intervention; N=523
Number of subjects: 1049
Study 20382179 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC); N=526
Number of subjects: 1049
Study 18759783 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 517
Study 16362784 — intervention group
Group type: EXPERIMENTAL
Intervention: Repp86 expression in OSCC
Number of subjects: 69
Study 16362784 — intervention group
Group type: COMPARATOR
Intervention: Normal oral mucosa
Number of subjects: 69
Study 16362784 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with Ki-67
Number of subjects: 69
Study 16362784 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with topoisomerase IIalpha
Number of subjects: 69
Study 16362784 — intervention group
Group type: EXPERIMENTAL
Intervention: Ki-67 and topoisomerase IIalpha levels
Number of subjects: 69
Study 12528093 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 15
Study 12528093 — intervention group
Group type: COMPARATOR
Intervention: Non-acupoint acupuncture
Number of subjects: 15
Study 12528093 — intervention group
Group type: COMPARATOR
Intervention: No-needle acupuncture control
Number of subjects: 15
Study 9987041 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA (Percutaneous Transluminal Coronary Angioplasty)
Number of subjects: 0
Study 9987041 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 0
Study 8700066 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular practice of Basic Life Support (BLS) skills; specific details on dosage and duration not available.
Number of subjects: 0
Study 8700066 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher-student ratio during BLS training; specific details not available.
Number of subjects: 0
Study 1897350 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 45
Study 1897350 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 45
Study 1897350 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 45
Study 1897350 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine infusion
Number of subjects: 45
Study 1897350 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin infusion
Number of subjects: 45
Study 6349411 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural buprenorphine (60 micrograms in 10 ml)
Number of subjects: 0
Study 6349411 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine (2 mg in 10 ml of normal saline)
Number of subjects: 0
Study 31522031 — intervention group
Group type: EXPERIMENTAL
Intervention: tiotropium/olodaterol 5/5 μg via Respimat inhaler
Number of subjects: 20
Study 31522031 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 28723852 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin barrier cream applied 3 times a day
Number of subjects: 33
Study 28723852 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin barrier cream
Number of subjects: 33
Study 28723852 — intervention group
Group type: COMPARATOR
Intervention: Control group (no skin barrier cream)
Number of subjects: 33
Study 26600564 — intervention group
Group type: EXPERIMENTAL
Intervention: BiOSS LIM stent
Number of subjects: 202
Study 26600564 — intervention group
Group type: COMPARATOR
Intervention: rDES
Number of subjects: 202
Study 26600564 — intervention group
Group type: EXPERIMENTAL
Intervention: BiOSS LIM stent (FKBI subgroup)
Number of subjects: 202